VCP-Eribulin

VCP-Eribulin consists the ADCs linker (VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. VCP-Eribulin is an Eribulin-based agent for antibody conjugates[1].

Product Specifications

CAS Number

[2130869-17-7]

UNSPSC

12352203

Target

Drug-Linker Conjugates for ADC

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vcp-eribulin.html

Solubility

10 mM in DMSO

Smiles

C=C1C[C@@]2([H])O[C@@]1([H])CC[C@]3([H])O[C@](C([C@H](C)C3)=C)([H])C[C@@]4([H])[C@]([C@@H](OC)[C@@H](C[C@H](O)CNC(OCC5=CC=C(NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)N)=O)=O)C=C5)=O)O4)([H])CC(C[C@]6([H])O[C@]7([H])[C@]8([H])O[C@@]9(O[C@@]%10([H])[C@@](O[C@]8([H])[C@@]%10([H])O[C@@]7([H])CC6)([H])C9)CC2)=O

Molecular Formula

C59H86N6O16

Molecular Weight

1135.34

References & Citations

[1]Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.|[2]Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71 (2) :496-505.